DelveInsight's "Alpha-Mannosidosis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Alpha-Mannosidosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Alpha-Mannosidosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Alpha-Mannosidosis: An Overview
Alpha-mannosidosis (α-mannosidosis) is a rare lysosomal storage disorder with an autosomal recessive inheritance caused by mutations in the gene encoding for the lysosomal α-D-mannosidase.
It is caused by the lack of the lysosomal enzyme-alpha-mannosidase due to a mutation in MAN2B1, located on chromosome 19 that causes disturbed glycoprotein catabolism leading to an excessively high level of mannose-rich oligosaccharides in many tissues. This accumulation in various cells leads to various complications in patients. It is a progressive disease with mental retardation, skeletal and muscle abnormalities, central nervous system involvement, recurrent infections, psychiatric symptoms, and compromised pulmonary function.
Alpha-Mannosidosis Market Key Facts
-
As per the National Organization for Rare Disorders, Alpha-Mannosidosis is an ultra-rare progressive disorder that occurs in approximately 1 of 500,000 live births. Children are often born apparently normal, and their condition worsens progressively. Some children are born with ankle equinus or develop hydrocephalus in the first year of life (Malm et al.).
-
According to the Systematic Review of the Epidemiology of α-mannosidosis in 2017, the overall incidence of the disease globally ranges from 0.07 to 1.51 per 100,000 births. (Finocchiaro et al.).
-
Alpha-mannosidosis is inherited in an autosomal recessive manner and is reported to affect 1 in 1,000,000 people worldwide. At conception, each sibling of an affected individual has a 25% chance of being affected and a 50% chance of being an asymptomatic carrier.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Alpha-Mannosidosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Alpha-Mannosidosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Alpha-Mannosidosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Alpha-Mannosidosis Epidemiology, Segmented as -
-
Prevalent cases of Alpha-Mannosidosis in 7MM (2019–2032)
-
Severity-specific cases of Alpha-Mannosidosis (2019–2032)
-
Diagnosed and Treatable Cases of Alpha-Mannosidosis (2019–2032)
Learn How the Alpha-Mannosidosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/alpha-mannosidosis-market
Alpha-Mannosidosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alpha-Mannosidosis market or expected to be launched during the study period. The analysis covers the Alpha-Mannosidosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alpha-Mannosidosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Alpha-Mannosidosis Therapeutics Analysis
Enzyme replacement therapy is the standard therapy for a number of inherited diseases for treating lysosomal storage diseases. New treatment approvals in this rare space have given a boost to the R&D. Currently, a limited number of companies are working in the therapeutics space, such as Smart Pharma Therapeutics, Chiesi Farmaceutici, and other institutes; however, their research activities are expected to have a tremendous impact on the market to provide personalized medicine to this ultra-rare disease.
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/alpha-mannosidosis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Alpha-Mannosidosis Competitive Intelligence Analysis
4. Alpha-Mannosidosis Market Overview at a Glance
5. Alpha-Mannosidosis Disease Background and Overview
6. Alpha-Mannosidosis Patient Journey
7. Alpha-Mannosidosis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Alpha-Mannosidosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Alpha-Mannosidosis Unmet Needs
10. Key Endpoints of Alpha-Mannosidosis Treatment
11. Alpha-Mannosidosis Marketed Products
12. Alpha-Mannosidosis Emerging Drugs and Latest Therapeutic Advances
13. Alpha-Mannosidosis Seven Major Market Analysis
14. Attribute Analysis
15. Alpha-Mannosidosis Market Outlook (In US, EU5, and Japan)
16. Alpha-Mannosidosis Access and Reimbursement Overview
17. KOL Views on the Alpha-Mannosidosis Market
18. Alpha-Mannosidosis Market Drivers
19. Alpha-Mannosidosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/alpha-mannosidosis-market
Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
